Barkley Reporters
`
`Exhibit 3
`NikhiI Chopra
`4/6/2016
`5 Arielle Santos HPR. csn
`
`.
`PLAINTIFFS'
`TRIAL EXHIBIT
`
`
`
`C|P2087
`C|P_DYM_00000644
`
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`|PR2017-00807
`
`PTX0315
`
`3
`
`
`
`LOODO‘SLSOde
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`
`
`Exhibit 3
`NikhiI Chopra
`4/6/2016
`5 Arielle Santos HPR. csn
`
`.
`PLAINTIFFS'
`TRIAL EXHIBIT
`
`
`
`C|P2087
`C|P_DYM_00000644
`
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`|PR2017-00807
`
`PTX0315
`
`3
`
`
`
`LOODO‘SLSOde
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`
`
`
`
`
`
`
`
`common everyay pro -
`
`
`
`
`
`-An ignored but manageable problem
`
`
`
`oMiseries of everyday life
`
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`CIP_DYM_00000645
`
`
`
`ZOOOO‘SLSOXLd
`
`
`
`
`
`
`
`
`
`
`l in 6 people in India are said to be
`suffering from Rhinitis
`
`-Commonest allergy encountered in
`clinical practice
`
`~Constitutes more than 50% of all allergies
`seen in India
`
`
`
`SOOOO'S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`C|P_DYM_00000646
`
`
`
`
`
`
`
`Drowsiness
`
`
`
`
`Late
`
`Onset of action
`
`Rx for short duration
`
`Rebound congestion/
`side effects
`
`
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`C|P_DYN|__00000647
`
`
`
`170000'9[£0de
`
`
`
`
`
`
`
`Associated with
`
`
`
`
`
`
`
`
`
`Combination
`
`therapy
`
`is preferred
`
`
`
`
`
`
`
`90000‘9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`CIP_DYM_00000648
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`90000‘9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`
`
`
`
`
`
`The Complete Rhinitis-Control
`
`CIP__DYM__00000649
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I
`
`Decongestant
`
`— weeks
`
`Anihistai
`Decongestant
`
`:
`
`
`
`1.0000'9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`
`
`The Complete Rhin'ifis Control
`
`CIP_DYM_00000650
`
`
`
`
`
`
`
`
`
`
`
`Combination therapy is a preferred starter
`
`Combination therapy are for short duration
`
`Entry of INCS into the combination
`
` INCS
`
`
`
`
`
`+
`
`Cmarc Oct-Dec’03
`
`Antihistamine
`
`
`
`80000‘9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`
`The Complete Rhinitis Control
`
`C|P_DYM_00000651
`
`
`
`
`3300000:56EU-._<_._.Zmn__u_200>419:
`
`
`
`IlmmDmOm>_._.0m.r0mn_DmbajsmrrmO._.HUmmem
`
`
`
`
`90000.5130XTP
`
`
`
`
`mmwooooo_>_>n_n=0.|_<_._.zmn=n_zoo>I_I0:._
`
`
`
`IIImam—Om>_._K0m._.Omn_Dm._.<n_Dn__._.mO._.how“.me
`
`
`
`
`01000.5130XTP
`
`
`
`Cipla Introduces
`
`
`
`Azfifimtfifig ‘égQ mag «% E‘Eaziiaafimw 536% mag; may figway]
`WmW“M.MMWWMWMMMMMWWW.mmmwww.WMWMWMW.WMMWVMWMMhWMMMJ
`
`The Complete Rhini’ris Confrol
`
`
`
`HOOO'S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`11
`
`ClP__DYM_00000654
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Brand : Duo(Dual) + Nase(nose)
`
`The Duonase colour: Sky Blue, Symbolizes sky,openness, freshness
`and the vast opportunity
`
`The Duonase Logo:
`
`Rectangular Box: Vast opportunity
`
`Spray: To project the nasal spray and nose
`
`The Duonase Byline: The Complete Rhinitis Control
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`12
`
`C|P_DYM_00000655
`
`
`
`ZLOOO‘S[£0de
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Composition: Azelasfine 140 mcg + Fluficosone 50 mcg per spray
`
`Sales Pack: Bofile (9.8 ml)
`
`No. of doses: 70
`
`Price: RS. 168.00
`
`Sample pack: Boflle (3.5 ml)
`
`No. of doses: 25
`
`
`
`SLOOO'S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`13
`
`
`
`The Complete RhinItis Control
`
`CIP_DYM__00000656
`
`
`
`
`
`
`
`°The tirst intranasal, antihistamine-corticosteroid
`
`combination
`
`'Rapid and prolonged symptom control
`
`°Greater improvement in symptoms than
`antihistamine or corticosteroid alone
`
`~|ndicated for both allergic and non-allergic
`rhinitis
`
`- Convenient twice-daily dosing
`
`
`
`VLOOO'S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`14
`
`
`
`The Complete Rhinitis Control
`
`ClP_DYM_00000657
`
`
`
`
`
`
`
`
`Indication
`
`Moderate to severe symptoms Allergic and non-
`allergic vasomotor Rhinitis in adults >12 years
`
`Severe symptoms of Allergic Rhinitis in children
`above 5 years
`
`D050 9 e
`Adults and children 5 years and above
`
`1 spray/ nostril twice daily
`
`
`
`9LOOO'S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`15
`
`
`
`The Complete Rhinitis Control
`
`C|P_DYM_00000658
`
`
`
`
`
`
`
`
`
`
`
`Fluficasone is the mos’r prescribed INCS
`
`~Cmarc(Jcm-Feb'04),
`
`
`
`W24
`
`
`
`
`
`Fluticasone
`
`Mometasone
`
`Budesonide
`
`* Bcclomethasonc
`
`
`
`LIOOO‘S[£0de
`
` 34%
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPU LATED PROTECTIVE ORDER
`
`17
`
`
`
`The Complete RhiniIis Cohfrol
`
`CIP_DYM_00000660
`
`
`
`
`
`
`
`
`volume —
`growth
`
`
`
`de Mometasone
`
`Fluticasone fi Budeson
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Growth:
`
`Total market: 27%
`
`Value(cr)
`
`Units(lac)
`
`Fluticasone: 39%
`
`ORG FEB MAT‘04
`
`
`
`SLOOO'S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPU LATED PROTECTIVE ORDER
`
`1s
`
`The Complete Rhinitis Control
`
`C|P_DYIVI_00000661
`
`
`
`
`
`
`
`
`
`-Only topical antihistamine nasal spray available in India
`
`-Significant awareness among the Drs.
`
`-Azep from GR valued at 1.2 cr, gr 9.8%
`
`
`
`
`
`
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`19
`
`The Complete Rhinitis
`
`CIP_DYM_00000662
`
`
`
`GIOOO'S[£0de
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` units(lac)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`maown-~Budenase AQ (Gr: -8%)
`
`Metaspray (Gr: 101%)
`
`
`
`‘Flomist(Gr: 7%)
`
`mmTotakGr: 12 %)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2001-2002
`
`2002-2003
`
`2003-2004
`
`
`
`LZOOO‘S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`21
`
`Infernal dam
`
`C|P_DYM_00000664
`
`
`
`
`mmmooooo_>_>Dn:0.AEHZMDEZOO>410...—
`
`
`llmmDmOm>_._.0m._.0m‘n_om.._.<..5n=._.mOPFUNfimDm
`
`
`
`22000.5130XTP
`
`
`
`
`
`2005
`
`1980
`
`
`
`
`
`
`
`
`2000-
`
`1995-
`
`
`
`
`
`1990
`
`1985
`
`1975
`
`
`
`SZOOO'SLSOXLd
`
`WGHLYCONHDENUAL-
`SUBJECTTOSTPULATEDPROTECHVEORDER
`
`23
`
`C|P_DYM_00000666
`
`
`
`
`
`1600
`
`Unitsflac]
`
`
`
`.. 1400
`
`W 1200
`
`-— 1000
`
`~- 500
`
`EU":
`
`.4 600
`
`400
`
` »
`
`
`
`
`Nezaflo
`
`M etatop
`
`C|P_DYM_00000667
`
`
`
` Y3?
`
`E00 nase
`
`‘_
`FTLHcone Aquamet
`
`Fonnase R hino cort
`
`Flomist
`
`M etaspray Rhinocon Budenase
`A0
`A0
`
`Azep
`
`
`
`73000'9LSOXLd
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`24
`
`
`
`
`
`
`
`93000'9L90de
`
`2001-2002
`
`2002-2003
`
`2003-2004
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`25
`
`CIP_DYM_00000668
`
`arnal daia
`
`4:.
`
`0O
`
`
`
`units(lac)
`
`WBudenase AQ
`
`
`
`w§w Metaspray
`
`
`
`Flomist
`
`Wmmtal
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`With D uonase
`
`For ENTs
`
`°Se|i the concept of complete rhinitis control
`
`-lncrecrse the INS prescribing habit
`
`- Differentiate from competitors
`
`°A kind of re-iounching Flomist
`
`-Increcrse rapport with the ENTs
`
`olncreose support for other products
`
`
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`26
`
`C|P_DYM_00000669
`
`
`
`93000‘9[£0de
`
`
`
`
`
`With Duonase
`
`For Chest Phy/ Allergy spl
`
`°Encash the understanding of dual aspect of AR
`
`0 Replace the potential antihistamine+lNCS
`prescriptions
`
`- Differentiate from competitors
`
`°More follow-up prescription for Flomist/ Metaspray
`
`~Re-establish our undisputed commitment in
`respiratory
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`27
`
`ClP_DYM_00000670
`
`
`
`LZOOO‘S[£0de
`
`
`
`
`
`
`
`WimDuonase
`
`For Upper end Phy/ GP
`
`°Encash the short term prescribing hcrbiiL for AR
`
`- Develop the marker
`
`
`
`83000‘9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`28
`
`C|P_DYM_00000671
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mission Duonase
`
`Bow, Sow and Reap
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` w
`
`Jan-Feb
`
`Mar-Apr
`
`May-Jun
`
`Jul-Aug
`
`Sap-Oct
`
`Nov-Dec
`
`
`
`09000‘9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`30
`
`ORG data
`
`CIP__DYM__00000673
`
`
`
`
`
`
`
`
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`31
`
`C | P_DYM_00000674
`
`
`
`LSOOO'S[£0de
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`- Positioning Duonase as the first-choice prescription for AR with
`Flomist/ Metaspray as the follow-up
`
`- For chest phy/ Phy highlighting the concept of ‘One Airway-
`One Disease’ with Metaspray as the maintenance Option
`
`0 For ENTs studies on Fluticasone in Nasal polyps and sinusitis
`and its co-existence with AR
`
`- Positioning Montair as maintenance of AR or in severe cases
`of rhinitis
`
`
`
`ZSOOO‘S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`32
`
`
`
`The Complete Rhinitis Control
`
`ClP_DYNI_00000675
`
`
`
`
`
`
`
`Therapy Managers
`
`
`
`Meetings
`
`Allergy
`
`
`
`SSOOO'S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`33
`
`Camps/ clinics
`
` :.s=-,,«
`
`The Complete Rhinitis “Control
`
`CIP_DYM_00000676
`
`
`
`
`
`Pafienl
`
`Educafion
`
`leaflet
`
`
`
`Pafienl
`
`Educafion
`
`Pos’rer
`
`How to use
`
`nasal spray
`
`iearofi
`
`
`
`179000'9[£0de
`
`HIGHLY CONFlDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`34
`
` ,
`
`.I;
`
`The Complete Rhinitis Control
`
`CIP_DYM_00000677
`
`
`
`
`
`
`
`
`~Targef all the prescribers of
`Azelas’rine($pecifically Azep from GR) and switch
`
`them to Duonase
`
`-Targe’r ’rhe prescribers of competitor Flu’ricasone
`
`brands and convert them to DUOHCISG
`
`
`
`99000‘9[£0de
`
`HIGHLY CONFIDENTIAL ~
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`35
`
`C|P_DYM_00000678
`
`
`
`
`
`
`
`
`
`
`
`5Teaser1
`
`~Teaser 2
`
`- PDA
`
`- Data sheet
`
`- Lit.'on SAR
`
`- Lit. on PAR
`
`- Lit. on Vasomotor
`
`-C|ip Board
`
`- Pocket Calendar
`
`- Rx Pad
`
`oPen
`
`-Visiting card Holder
`
`~ ~Gitt
`
`
`
`1.9000'9[£0de
`
`HlGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`37
`
`
`
`The Complete Rhinitis Control
`
`ClP_DYM_00000680
`
`
`
`
`
`
`
`
`Fresh look at our approach to AR
`
`Complete relook to ENT segment, MSL and
`
`coverage
`
`- Promote. Duonase-the great idea, for
`complete rhinitis control
`
`0 Build up the whole Allergic Rhinitis basket
`
`
`
`89000‘9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`38
`
`
`
`The Complete Rhinitis Control
`
`ClP_DYM_00000681
`
`
`
`
`
`
`mmocooooS_>n_n=0..._<_._.Zm_n__u_200>419:
`
`
`
`IImmDmOm>_._.0m.r0mn_awh<43n=hwO._.._.0m=..me
`
`
`
`
`o40oO5130XTP
`
`
`
`
`
`
`
`I?
`
`in (3 ympia am mini m in:-
`
`rsafl‘iesrhrg Fm in R3} 3.2::1iét'i-s.’
`
`- w, <-~».-m\--.-ww:- gnu/'1». hwy-“M .\ “Tawnyowmac“.‘,‘..m.m
`
`
`
`WOOO'S[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STlPULATED PROTECTIVE ORDER
`
`41
`
`CIP_DYM_00000684
`
`
`
`"wwuu-mw.«mm-nmm«mnmmmmumww
`iii. aéié'lgm m'éiiéisiéi";
`
`fian-
`
`fixtffifirfl {sly gamma :1
`
`dixmm wmhiwéiéfi,
`
`j§fli§§flli¥tii’ii§£t"
`af'fitmfiing m m 333% inf an».
`
`{Ea-33m; «:1: 13315735 ;:
`smié‘eaxsgy 1:: £22 m um 133 ad
`
`in. aijmimi piflfifi'ififi and;
`mfisgtix
`mam fimn 758% a?" ti“
`
`
`mm: in End.
`
`
`
`Mk: fig.
`
`
`
`
`.mmooooooE>Qn=0._<_._.zmn=n_200>419....
`
`
`
`
`IImun—m0m>:.om:.0mn_Duh/.15meO._.HOME—3w
`
`
`
`
`24000.5130XTP
`
`
`
`
`
`
`
`
`
`
`
`,wmwooooolE>DlE0.:_<_._.zmn__n_200>.._IG_I
`
`
`
`
`
`
`
`
`
`Mmomom_>:.0m_.r0mn_DmHSDEHwOHHOE.me
`
`34000.5130XTP
`
`
`
`
`
`
`
`
`
`
`Ifimitsgmuamg gM-m, Imm‘fi amE waif
`
`
`
`Et'wfltmf'y‘ ‘Mli:’§'§l;}‘"
`
`0mm;
`
`against as: $42 Emit- 33fl¥t~dc
`3’
`.I
`
`
`
`12*. m: Iaizmwwii
`
`
`1: flutnlmissd and:nédzéflmt‘itn;
`y ME"?
`)4
`3.3 x: 3’§=‘{«: (I? Hurt: {I
`
`z «w-
`
`
`
`
`
`
`
`Nag-3.533 whim E5 minmms‘
`~‘ mail Iwmntihm‘ in the:
`Wan-av
`
`fiimwxim maze: 4m mmgmmci‘ m
`. wiixmizw?
`
`
`
`917000'9[£0de
`
`
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`45
`
`CIP_DYM_00000688
`
`
`
`
`
`
`
`Emmiyfatman?awm.wfiwflwgfifiwfim
`
`
`
`Ema»».qu_.mEE...5.3.2.”3:1
`
`!
`mmoooooolSFDlnzo..._<_l_.Zm_n=u_ZOO>419:
`
`
`
`
`
`MY. “MM—w
`--«
`
`.{v
`
`.MEE6U......15zw“
`
`
`
`mmDmOm>_._.0m._.0mn_Dmk<43mrrw0khomfimnw
`
`PTX0315-00046
`
`
`
`
`
`
`
`17000-9LSOde
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`47
`
`ClP_DYM_00000690
`
`
`
`
`
`Rh inftis Genital
`
`The flu: isnhimmmt Ems'iha‘gmméflew
`wnfiwsmwi-vfi. camibiflatmw:
`
`
`wmwggywwmfi
`
`fiagiifi and. girwimgmi wmpmm warm}
`/ .wWMWWNWfigmwmm “my.
`. .
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`817000'9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`48
`
`C|P_DYM_00000691
`
`
`
`
`
`
`
`
`
`617000'9[£0de
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO-STIPULATED PROTECTIVE ORDER
`
`49
`
`C|P_DYM_00000692
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
